Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,087 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D. Redfield RR, et al. Among authors: green c. Am J Transplant. 2019 Nov;19(11):3035-3045. doi: 10.1111/ajt.15514. Epub 2019 Jul 23. Am J Transplant. 2019. PMID: 31257724 Free PMC article. Clinical Trial.
Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.
Looney CM, Strauli N, Cascino MD, Garma H, Schroeder AV, Takahashi C, O'Gorman W, Green C, Herman AE. Looney CM, et al. Among authors: green c. Clin Immunol. 2023 Mar;248:109265. doi: 10.1016/j.clim.2023.109265. Epub 2023 Feb 14. Clin Immunol. 2023. PMID: 36796471 Free article.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Daver NG, et al. Among authors: green c. Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362. Blood. 2023. PMID: 36265087 Free PMC article. Clinical Trial.
Quantitative Comparison of Conventional and t-SNE-guided Gating Analyses.
Toghi Eshghi S, Au-Yeung A, Takahashi C, Bolen CR, Nyachienga MN, Lear SP, Green C, Mathews WR, O'Gorman WE. Toghi Eshghi S, et al. Among authors: green c. Front Immunol. 2019 Jun 5;10:1194. doi: 10.3389/fimmu.2019.01194. eCollection 2019. Front Immunol. 2019. PMID: 31231371 Free PMC article.
Automatic Population of the Case Report Forms for an International Multifactorial Adaptive Platform Trial Amid the COVID-19 Pandemic.
King AJ, Higgins L, Au C, Malakouti S, Music E, Kalchthaler K, Clermont G, Garrard W, Huang DT, McVerry BJ, Seymour CW, Linstrum K, McNamara A, Green C, Loar I, Roberts T, Marroquin O, Angus DC, Horvat CM. King AJ, et al. Among authors: green c. AMIA Jt Summits Transl Sci Proc. 2024 May 31;2024:276-284. eCollection 2024. AMIA Jt Summits Transl Sci Proc. 2024. PMID: 38827056 Free PMC article.
4,087 results